Prana Biotechnology secures orphan designation for PBT434 in MSA
Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple
Continue readingCoverage of Global Pharma Industry News
Australian biotech company Prana Biotechnology has secured Orphan Drug designation for PBT434, its lead molecule, for the treatment of Multiple
Continue readingAgeneBio, a US-based CNS biopharma company, enrolled the first patient in a phase 3 clinical trial to study the efficacy
Continue readingUS biopharma company Spectrum Pharmaceuticals has agreed to offload seven of its FDA-approved hematology/oncology drugs to Acrotech Biopharma, a subsidiary
Continue readingUS biotech company X-Rx said that the US Food and Drug Administration (FDA) has accepted its investigational new drug application
Continue readingCAMBRIDGE, Mass.–(BUSINESS WIRE)–Tamr Inc. today announced it has joined Accenture’s open partner ecosystem, designed to help independent software vendors (ISVs) and
Continue readingRubraca EC approval : US biotech company Clovis Oncology has secured approval for an additional indication for its cancer drug
Continue readingEusa Pharma has completed acquisition of the global rights of idiopathic multicentric Castleman’s disease drug (iMCD drug) Sylvant (siltuximab) from
Continue readingTakeda acquisition of Shire : Japanese pharma company Takeda Pharmaceutical wrapped up its previously announced acquisition of Shire, an Irish
Continue readingLilly acquisition of Loxo Oncology : US pharma giant Eli Lilly and Company (Lilly) has signed an all-cash deal worth
Continue readingBristol-Myers Squibb acquisition of Celgene : US biotech company Celgene has agreed to be acquired by Bristol-Myers Squibb in a
Continue reading